GTRI flags proposed US generic-drug tariffs as major risk for Indian pharma exporters
A proposed US tariff path—0% for two years from August 1, then 100% for a year and 200% thereafter—could pressure Indian drugmakers. India sent $9.7 billion, or 37.7%, of its $25.8 billion pharmaceutical exports to the US in 2025, according to GTRI.
GTRI said proposed US tariffs of up to 200% on generic drugs could significantly hit Indian pharma exports, particularly higher-value formulations. India sends 37.7% of its pharmaceutical exports to the US, though Indian manufacturers with US facilities may be better positioned.
Why this matters
No related recent signals are provided; the proposed tariff path highlights US market-concentration risk for Indian pharmaceutical exporters.
Retail-company signals are accelerating, up 1,000,100% QoQ.